Fractyl Health, Inc.
GUTSNASDAQHealthcareBiotechnology
Previous close
$0.78
+$0.0949 · +13.85%
GUTS company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
21
Expensive
Momentum
26
Weakening
Sentiment
43
Mixed
Risk resilience
20
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteFractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Harith Rajagopalan
- Listed since
- Feb 2, 2024
- Employees
- 100
Market position
Day range
Current $0.78
52-week range
Current $0.78
- Open
- $0.685
- Previous close
- $0.6851
- Volume
- 3.39M
- 1.86× average
- Average volume
- 1.83M
- Average daily volume
- Market cap
- 123.75M USD
- Beta
- 2.32
- Market reference 1
- 50-day average
- $0.7589
- +2.77% above average
- 200-day average
- $0.9921
- -21.38% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 317.52M USD
- P/E (TTM)
- -0.71×
- P/B (TTM)
- -74.32×
- P/S (TTM)
- 0×
- EV / EBITDA
- -2.27×
- Earnings yield
- -41.77%
- Free cash flow yield
- -26.94%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -1490.32%
- Return on assets
- -116.11%
- Return on invested capital
- -89.50%
Financial health
- Debt / equity
- -36.48×
- Current ratio
- 4.78×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 93K USD | 120K USD | — | — |
| Cost of goods sold | — | 50K USD | 77K USD | 452K USD | — |
| Gross profit | — | 43K USD | 43K USD | −452K USD | — |
| Research and development | 74.54M USD | 70.47M USD | 38.04M USD | 34.35M USD | 26.44M USD |
| Selling, general, and administrative | 22.28M USD | — | — | 14.58M USD | 10.49M USD |
| Operating expenses | 96.82M USD | 93.57M USD | 50.88M USD | 48.93M USD | 36.93M USD |
| Interest income | 1.54M USD | 4.15M USD | 1.26M USD | 797K USD | — |
| Interest expense | — | — | — | — | 1.44M USD |
| Depreciation and amortization | 1.13M USD | 677K USD | 286K USD | 452K USD | 676K USD |
| Operating income | −96.82M USD | −93.53M USD | −50.84M USD | −49.39M USD | −36.93M USD |
| Net income | −140.95M USD | −68.69M USD | −77.09M USD | −46.45M USD | −38.74M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 36%
- 4 beats, 6 misses, 1 met estimate
- Average EPS surprise
- -165.52%
- 11 comparable reports
- Latest EPS result
- -0.12
- Estimate -0.14 · Beat by 11.11%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$5.00
541.03% upsideRecent analyst actions
GUTS news
GUTS peers
ETFs holding GUTS
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research GUTSresearch.disclaimer